LQDA · Liquidia Corp
$28.64
+0.65 (+2.32%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$6.13B
Shares
89.51M
Volume · Oct 2
8.4M
Avg daily vol (3M)
2.16M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.64
Open$26.69
Day$26.31–29.18
52W close$21.90–91.03
Avg vol 30d2.8M
Short int12.4M · 13.8% float · 11.5d
Short vol35%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 5 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$450.91M
Trailing 12 months
Net income (TTM)
$138.61M
Trailing 12 months
Revenue growth YoY
+1,842.7%
Year over year
Operating margin
37.4%
Trailing 12 months
P / E (TTM)
20.0
Trailing earnings · reciprocal yield 5.0%
FCF yield
2.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.5%
Year over year · more shares
Price change (1Y)
+26.9%
Trailing year
Short interest
13.8%
Latest settlement · 11.5 days to cover
AI Brief
Q2 FY26 earnings call · Aug 12, 2026
Q2 FY26
TL;DR. Liquidia reported Q2 2026 YUTREPIA net product sales of $170.4 million, up 31% Q/Q, with $96.3 million adjusted EBITDA, $74.7 million net income, and $284.2 million in cash, while management reaffirmed confidence in achieving more than $1 billion in net revenue in 2027.
Bullish
- + Cash balance of $284.2M, up $61.4M Q/Q and $93.5M year-to-date, funding pipeline investment
- + YUTREPIA approaching 30% of the inhaled prostacyclin market, with growth exceeding the entire category
- + Management confidence in achieving more than $1 billion in net revenue in 2027
Bearish
- − Ongoing patent litigation with United Therapeutics seeking injunctive relief could block YUTREPIA sales
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−47%
below
Price vs 50-day avg
−60%
below
RSI (14)
20
oversold
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−58%
trailing
6-month return
−26%
trailing
YTD return
−17%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $72 › 200d $54 — 50d above 200d
Institutional flow
Accumulating
2 of 342 funds reported for Sep 30 · net +25 sh shares · +2 new
Insider flow
Distributing
Net -$37.3M over 90 days · 100% sells
Short interest
Rising
13.83% of float · ▲ +4.4% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
342 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+1031%
Y/Y
EPS growth
+51%
Y/Y
Free cash flow
$-40.0M
Balance sheet
$73.4M
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
21.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
At least $1 billion in 2027
· in 2027
at least $1B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−47%
Bearish
Price vs 50-day avg
−60%
Bearish
RSI (14)
20
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $72 › 200d $54 — 50d above 200d
Institutional flow
Accumulating
2 of 342 funds reported for Sep 30 · net +25 sh shares · +2 new
Insider flow
Distributing
Net -$37.3M over 90 days · 100% sells
Short interest
Rising
13.83% of float · ▲ +4.4% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
342 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22
Now $29 · 10%
Range high $91
vs 200-day avg -47%
vs 50-day avg -60%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | $96.3M | the second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income 74.72M
+3.82M Interest expense, net
+6.98M Income tax expense
+400K Depreciation & amortization
+10.37M Stock-based compensation
= Adjusted EBITDA 96.29M
|
|||
| Annualized net product sales run-rate | $682M | exited Q2 2026 | — |
| Patients started on treatment since launch in June 2025 | 5,000 | between launch in June 2025 and July 31, 2026 | — |
| Prescribers who referred patients for YUTREPIA | 1,100 | through 31-Jul 2026 | — |
| Prescribers with 5+ referrals | 30% | through 31-Jul 2026 | — |
| Prescription to patient start conversion rate | 85% | as of July 31, 2026 | — |
| Total number of prescribers since launch | 1,100 | as of July 31, 2026 | — |
| Unique patient prescriptions (YUTREPIA) | 5,900 | through 31-Jul 2026 | — |
| YUTREPIA® (treprostinil) inhalation powder net product sales | $170.4M | the second quarter of 2026 | +2514.7% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LQDA
this stock
Liquidia Corp
|
$6.13B | -17.0% | +1031.2% | — | 13.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LQDA | -58.2% | -58.3% | -26.3% | -5.4% | -17.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -57.9% | -57.8% | -38.5% | -6.3% | -29.8% |